Jupiter Therapeutics
Creating cellular vesicles that can be used to deliver materials of interest to specific locations in the body.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
N/A | - | ||
| Total Funding | 000k | ||
Jupiter Therapeutics operates as a biotechnology firm focused on developing cell-membrane-based therapeutics. The company utilizes cell engineering to create customized vesicles for applications in immuno-oncology and gene therapy. This approach is designed to leverage information from cell-membrane studies to advance treatments related to CAR T-cells and bi-specific antibodies, enabling medical researchers in these fields.
The company's history includes securing a grant of $256K on January 1, 2020, followed by a Seed Round of $1M on June 22, 2020. It also participated in an accelerator/incubator program starting January 1, 2021.
Keywords: cell engineering, immuno-oncology, gene therapy, cell-membrane therapeutics, customized vesicles, CAR T-cell therapy, bi-specific antibodies, medical research tools, biotechnology, therapeutic development, oncology treatment, genetic medicine